Infusion of donor-derived CMV peptide-specific CTL after allogeneic HSCT

ACTRN12605000213640

Status	RECRUITING
Phase	Phase 1
Sponsor	Department of Haematology, Westmead Hospital
Enrollment	12 participants

Plain Language Summary

This study tests whether transferring specialised immune cells (called CMV-specific cytotoxic T lymphocytes or CTLs) from a stem cell donor to a patient who has received a stem cell transplant can prevent or treat cytomegalovirus (CMV) infection. CMV is a common virus that can cause serious illness in people with weakened immune systems after transplant.

You may be eligible if:
- You have received an allogeneic (donor) blood stem cell transplant
- It has been more than 28 days since your transplant
- Your donor is HLA-A*0201 positive and CMV positive
- You had a matched sibling donor (5/6 or 6/6 match) or a 6/6 matched unrelated donor
- Your graft-versus-host disease (GVHD) is less than grade II at the time of infusion
- You have not recently received anti-lymphocyte therapy

You may NOT be eligible if:
- There are no additional specific exclusion criteria listed beyond meeting the above requirements

Talk to your doctor about whether this trial might be right for you.

Key Eligibility Criteria

Inclusion (1)

- HLA-A*0201 pos and CMV seropositive donor, 5/6 or 6/6 sib match or 6/6/MUD, GVHD < grade II at the time of infusion, >day 28 post allogeneic HSCT, no recent anti-lymphocyte globulin.

Locations (1 total)

Australia

DISCLAIMER: This document is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider before enrolling in any clinical trial. Information may not be up to date — verify details at anzctr.org.au. Generated by ClinicalTrialsFinder.org.